Physician profile
Talal M Nsouli
NPI 1639271653
$75,751.19
in general payments reported to CMS, 2019-2025
26 companies · $6,626 in 2025
The $6,626 reported for 2025 was more than what 86% of Clinical & Laboratory Immunology (Allergy & Immunology) providers received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $9,790 · 2021: $4,959 · 2022: $16K · 2023: $14K · 2024: $13K · 2025: $6,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $6,118 · Travel and Lodging: $49.00 · Consulting Fee: $22.44 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,775.00 |
| Food and Beverage | $6,117.52 |
| Travel and Lodging | $49.00 |
| Consulting Fee | $22.44 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $53,495.81 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Amgen INC. | $9,833.04 | 2021-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $6,668.24 | 2019-2020 | |
| Glaxosmithkline, LLC. | $1,192.67 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,058.54 | 2019-2025 | |
| Pfizer INC. | $641.45 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $566.08 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $451.11 | 2019-2025 | Xolair |
| Optinose US, INC. | $302.80 | 2019-2024 | |
| Pharming Healthcare, INC. | $271.04 | 2020-2025 | Ruconest |
| Csl Behring | $236.59 | 2019-2025 | Haegarda, Andembry |
| Kaleo, INC. | $187.18 | 2019-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $146.28 | 2022-2024 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $129.13 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $105.56 | 2025 | Neffy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $96.59 | 2019-2024 | Immunocap |
| Hikma Pharmaceuticals USA | $65.88 | 2023 | Ryaltris |
| Grifols USA, LLC | $57.55 | 2025 | Xembify |
| Abbvie INC. | $56.88 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.32 | 2024-2025 | Cuvitru |
| Mylan Specialty L.P. | $31.06 | 2019 | |
| Dermavant Sciences, INC. | $26.94 | 2024 | Vtama |
| Ionis Pharmaceuticals, INC. | $24.91 | 2025 | Dawnzera |
| Adma Biomanufacturing LLC | $22.44 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.87 | 2021 | |
| Shire North American Group INC | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talal Nsouli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.